EchoStar Corporation Common Stock vs Liquidia Corporation Common Stock — how do they compare? EchoStar Corporation Common Stock trades at $87.14 (market cap $26.63B), while Liquidia Corporation Common Stock trades at $33.5 (market cap $2.40B). The key difference: EchoStar Corporation Common Stock is far larger — about 11.1× Liquidia Corporation Common Stock's market cap, and EchoStar Corporation Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 6 Days and Liquidia Corporation Common Stock for 0 Days on average.
| ECHO | LQDA | |
|---|---|---|
Market Cap | $26.63B | $2.40B |
Volume | 2,918,300 | 2,857,547 |
Sector | Media | Health |
52-Week High | $141.80 | $91.03 |
52-Week Low | $66.93 | $22.02 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.68B | $2.30B |
Signals from Pluang's Aura AI — not financial advice
ECHO trades at $91.56, down 3.72% over 24 hours, with a neutral technical signal and mixed earnings history including a significant Q2 2026 beat. The company reported a net loss of $14.50 billion in 2025, with negative cash flows, though revenue remains substantial at $15.00 billion. Recent news highlights institutional investments and a strategic partnership with United Airlines for in-flight streaming.
Analyst consensus is strongly bullish with a $134.00 price target, but high risks stem from persistent losses, negative cash flow, and the Hughes unit's bankruptcy. The stock's appeal hinges on turnaround execution and debt reduction efforts outweighing fundamental weaknesses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →